Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $20.731 million which missed the analyst consensus estimate of $21.600 million by 4.02 percent. This is a 20.86 percent decrease over sales of $26.195 million the same period last year.